Amgen Stock Lags S&P 500 by 12.5% Despite Earnings Beat

Amgen shares are trading at a material discount to its sector and the broader market following its Q1 2026 earnings report, which was released in early May. The biotechnology giant reported adjusted earnings per share of $4.28, surpassing analyst estimates of $4.12. Despite this beat, the stock's year-to-date performance of -2.1% lags the S&P 500's 10.4% gain by over 12.5 percentage points, highlighting a persistent valuation disconnect. This performance data was reported by finance.yahoo.com on June 5, 2026.

Context — why this matters now

Large-cap biotech valuations are under intense scrutiny as investors rotate capital into high-growth therapeutic areas like gene editing and weight-loss drugs. The last comparable period of pronounced underperformance for a bellwether like Amgen was in 2021, when the stock declined 8% for the full year while the SPDR S&P Biotech ETF (XBI) rose over 40%, a divergence of nearly 50 percentage points. That period reflected a market preference for speculative growth over established cash flow.

The current macro backdrop features the 10-year Treasury yield at 4.31%, providing a higher hurdle rate for discounting future earnings and pressuring long-duration assets. The catalyst for the current valuation debate is Amgen's successful navigation of patent cliffs for legacy blockbusters like Enbrel, offset by the integration of Horizon Therapeutics. The critical question is whether the market is correctly pricing Amgen's transition to a new portfolio of drugs or is overly discounting its future prospects due to a lack of near-term explosive growth catalysts.

Data — what the numbers show

The core numbers illustrate the valuation gap. Amgen's current forward price-to-earnings ratio is 10.8x, based on consensus 2027 EPS estimates. This stands in stark contrast to the iShares Biotechnology ETF's (IBB) forward P/E of 18.2x, representing a discount of roughly 40%. Amgen's price-to-sales multiple of 4.1x is also below the sector median of 5.5x.

The company's financial health metrics show strength. Net debt stands at $55.2 billion, a reduction from the post-Horizon acquisition peak. The dividend yield is 3.4%, significantly above the S&P 500 average of 1.5%. In the first quarter, Amgen generated $7.2 billion in revenue, a 22% year-over-year increase, with new products like Tezspire and the Horizon portfolio contributing meaningfully. A key before/after comparison shows the stock traded at a 15% premium to the sector P/E in 2019; it now trades at a 40% discount.

Analysis — what it means for markets / sectors / tickers

The undervalued stock thesis hinges on Amgen's stable cash generation funding a rich dividend and debt reduction, while its pipeline, including obesity candidate MariTide, offers optionality. If the market re-rates Amgen toward the sector average P/E, a technical target of $340 per share is feasible, representing a 25% upside from current levels near $272. This would benefit large-cap value funds and dividend-focused strategies that have maintained positions.

The counter-argument, or value trap risk, is that the discounted multiple persists indefinitely due to lower organic growth expectations. Sectors like medical devices (e.g., Medtronic) and mature pharma (e.g., Pfizer) face similar headwinds, trading at depressed multiples. A key risk is clinical or commercial setbacks for key pipeline assets, which would cement the low-growth narrative. Positioning data indicates hedge funds have been net sellers, while long-only institutional ownership has remained stable, suggesting a lack of conviction from active traders.

Outlook — what to watch next

Immediate catalysts will determine the stock's direction. The Phase 2 data readout for MariTide in obesity, expected by Q4 2026, is the most significant binary event. Positive data could trigger a substantial re-rating, while disappointing results would validate bearish views. The next earnings report on July 24, 2026, will provide an update on the sales trajectory for newer launches like Tezspire and Uplizna.

Key technical levels to monitor include strong support at the 200-day moving average of $265 and the 52-week high resistance at $295. A sustained break above $295 on heavy volume would signal institutional accumulation and a potential trend change. Investors should also watch for peer earnings from companies like Gilead Sciences and Vertex Pharmaceuticals for relative performance cues.

Frequently Asked Questions

Is Amgen a good dividend stock?

Amgen offers an attractive dividend yield of 3.4%, which is more than double the S&P 500 average. The dividend appears secure, supported by strong and predictable cash flow from its mature product portfolio. The company has a history of consistent annual increases, making it a candidate for income-focused portfolios within the healthcare sector. However, dividend growth has been modest in recent years, averaging around 5% annually.

How does Amgen's valuation compare to Pfizer's?

Amgen and Pfizer are both large, mature pharmaceutical companies facing similar investor skepticism about growth. Amgen trades at a forward P/E of 10.8x, while Pfizer trades at approximately 11.5x. The key difference lies in their pipeline exposure; Amgen has a major candidate in the lucrative obesity market with MariTide, whereas Pfizer is facing a more imminent revenue cliff from its COVID-19 products. Amgen's net margin of approximately 30% also exceeds Pfizer's.

What is the biggest risk to Amgen's stock?

The predominant risk is pipeline failure, specifically for MariTide. The obesity market is dominated by Novo Nordisk and Eli Lilly, and any sign of inferior efficacy or safety for Amgen's candidate would remove a primary catalyst for multiple expansion. Secondary risks include faster-than-expected biosimilar erosion for key drugs and a deterioration in the debt profile if the company pursues another large acquisition. Macro risks like higher interest rates also pressure high-dividend, slower-growth stocks.

Bottom Line

Amgen presents a classic value proposition where strong fundamentals meet skeptical growth expectations, with MariTide data poised to break the stalemate.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.